May restricted specificity of commercially available plasmin inhibitor activity assays affect correct diagnosis of antiplasmin deficiency?

Blood Coagul Fibrinolysis. 2019 Jan;30(1):52-53. doi: 10.1097/MBC.0000000000000788.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antifibrinolytic Agents / pharmacology
  • Antifibrinolytic Agents / therapeutic use*
  • Hemorrhagic Disorders / diagnosis*
  • Hemorrhagic Disorders / drug therapy*
  • Hemorrhagic Disorders / pathology
  • Humans
  • alpha-2-Antiplasmin / deficiency*

Substances

  • Antifibrinolytic Agents
  • alpha-2-Antiplasmin

Supplementary concepts

  • Anti-plasmin deficiency, congenital